Neural Cell News

Neural Cell News is an online resource covering the latest research in neuroscience, neural stem cells, and neurological conditions.

Subscribe|Follow Us On

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

April 1, 2026

[Cyclerion Therapeutics, Inc.] Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc., announced that they have entered into a definitive merger agreement for an all-stock transaction.

Oligodendrocyte Precursor Cells-Microglia Crosstalk via BMP4 Drives Microglial Neuroprotective Response and Mitigates Alzheimer’s Disease

April 1, 2026

[Signal Transduction and Targeted Therapy] The authors found that Bmp4 produced by late-stage oligodendrocyte precursor cells, termed committed oligodendrocyte precursors, acts as a critical signal shaping microglial neuroprotective programs in the context of amyloid pathology.

UBQLN2 Links Proteotoxicity with Lipid Metabolism in Neurodegeneration

April 1, 2026

[Nature Neuroscience] Through multi-omic analyses of iPSC-derived neurons harboring disease-associated Ubiquilin 2 (UBQLN2) mutations, researchers uncovered UBQLN2 as a molecular hub linking lipid dysregulation and proteostasis, the perturbation of which contributes to neurodegeneration.

Deletion of SPI1 in Microglia Exacerbates Amyloid Pathology by Impairing Microglial Response in Alzheimer’s Disease Models

April 1, 2026

[Neuron] Investigators demonstrated that the selective deletion of Spi1 in microglia exacerbates Alzheimer’s disease-related pathologies in an amyloid mouse model.

RFC4 Drives Temozolomide Resistance in Glioblastoma by Activating STK38-BECN1-Dependent Autophagy

April 1, 2026

[Nature Communications] Multi-omics analyses and molecular experiments revealed that temozolomide-induced chromatin accessibility enables transcription factor YY1 to bind the RFC4 promoter and upregulate its expression.

Microglial Fructose Metabolism Is Essential for Glioblastoma Growth

April 1, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Scientists demonstrated that microglia uniquely express the fructose transporter GLUT5 and are the only immune cells in the glioblastoma microenvironment capable of metabolizing fructose.

Astrocytic AEBP1-NPAS3-LIPA Pathway Coordinates Cholesterol Homeostasis to Regulate Alzheimer’s Pathology

April 1, 2026

[Cell Reports] By integrating human bulk transcriptomes with single-nucleus RNA sequencing, researchers identified adipocyte enhancer-binding protein 1 (AEBP1) as an astrocyte-enriched factor upregulated in Alzheimer’s disease.

MEG3 in Glioma Stem Cells Promotes Glioblastoma Angiogenesis through FUBP3-Mediated VGF Expression

April 1, 2026

[Clinical and Experimental Medicine] Investigators identified that the expression of maternally expressed gene 3 (MEG3), a tumor-suppressive long non-coding RNA, is negatively correlated with patient prognosis.

Nanomaterials for Alzheimer’s Disease: Emerging Strategies in Diagnosis and Therapy

April 1, 2026

[Journal of Nanobiotechnology] Scientists presents a comprehensive landscape of recent advances in nano-enabled targeting techniques, with a focus on the target therapy of neuron, microglia, astrocyte, Aβ, Tau, mitochondria, and iron.

Johns Hopkins Researchers Awarded $15 Million to Develop Platform to Study Neurological Diseases and Screen Chemicals Using ‘New Approach Methodologies’

March 19, 2026

[Johns Hopkins Bloomberg School of Public Health] A team of Johns Hopkins researchers has been awarded a five-year $15 million grant from the NIH to develop a platform to test potential new treatments for neurological diseases such as Alzheimer’s, and to screen for harmful chemicals.

Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan

March 11, 2026

[Sumitomo Pharma Co., Ltd.] Sumitomo Pharma Co., Ltd. and and RACTHERA Co., Ltd., announced that Sumitomo Pharma has obtained conditional and time‑limited approval in Japan for the manufacturing and marketing authorization of the allogeneic iPS cell‑derived dopaminergic neural progenitor cell product AMCHEPRY^® for the indication of the improvement of motor symptoms in patients with Parkinson’s disease who have an inadequate response to existing pharmacological therapies.

Five Global Teams Awarded $125 Million to Take on the Toughest Challenges at the Frontiers of Cancer Science

March 6, 2026

[Cancer Grand Challenges (Business Wire)] Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute in the US and Cancer Research UK, announced a major $125m commitment to propel cancer research into uncharted territory.

Neural Cell News helps scientists keep pace with the latest research, reviews, and industry developments in neuroscience. Specific research topics include neural development and neuroregeneration, neural signaling related to cellular responses and behavior, and synaptic plasticity. Research into the diagnosis, progression, cellular characteristics, and treatment of brain diseases such as Parkinson’s, Multiple Sclerosis, Alzheimer’s, Amyotrophic Lateral Sclerosis and various brain cancers, as well as brain damage resulting from infection, trauma, stroke, seizures, and tumors, is also covered.